More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in studyCNBC • 10/25/23
Biogen and Eisai release new Alzheimer's drug data that may support wider uptakeMarket Watch • 10/25/23
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On AlzheGlobeNewsWire • 10/25/23
New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's DiseaseGlobeNewsWire • 10/25/23
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 MeetingGlobeNewsWire • 10/19/23
Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?Zacks Investment Research • 10/13/23
FDA Approves Biogen's TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®GlobeNewsWire • 09/29/23
Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)Seeking Alpha • 09/26/23
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer's Disease in JapanGlobeNewsWire • 09/25/23
Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/11/23
Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient ManagementBusiness Wire • 09/06/23